Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect Study of TP-05 in Healthy Participants
NCT05720364Phase 1Completed
- Sponsor
- Tarsus Pharmaceuticals, Inc.
- Start
- Jan 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lotilaner in Lyme disease and malaria (3 arms), sponsored by Tarsus Pharmaceuticals, Inc. Primary endpoints: Concentration of TP-05 in whole blood, Exposure and PK of lotilaner in whole blood (AUC0-96hours) and 3 more. Started Jan 2023; status: completed.
02
Drugs
lotilaner
03
Conditions
Lyme diseasemalaria
Beyond the preview
Go deeper on NCT05720364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05720364.